Cardiovascular Drugs Market Updates

Cardiovascular Drugs Market size was valued at USD 169.98 Billion in 2023 and is poised to grow from USD 177.66 Billion in 2024 to USD 253.04 Billion by 2032, growing at a CAGR of 4.52% during the forecast period (2025-2032).

Global cardiovascular drugs market is highly competitive with the presence of local as well as global companies. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of global cardiovascular drugs market. 'Bristol-Myers Squibb Company ', 'Bayer AG ', 'Pfizer Inc. ', 'Johnson & Johnson ', 'Novartis AG ', 'Merck & Co. ', 'AstraZeneca ', 'Sanofi S.A. ', 'Gilead Sciences, Inc. ', 'Viatris ', 'AMGen ', 'United Therapeutics ', 'Daiichi Sankyo Co Ltd ', 'F. Hoffmann-La Roche AG ', 'Boehringer Ingelheim GmbH ', 'Abbott Laboratories ', 'Eli Lilly and Company ', 'GlaxoSmithKline plc ', 'Takeda Pharmaceutical Company Limited ', 'Astellas Pharma Inc. '

According to WHO, 60% to 85% of the population is sedentary. According to the CDC, approximately 31 million Americans over the age of 50 lead a sedentary lifestyle, and only one in four US adults receive recommended physical activity. This factor increases market growth.

Obesity and high cholesterol levels increase the risk of cardiovascular disease. The use of emergency medicine is commonly seen in hospitals, which has shown great potential for market growth. A large number of patients receive personal care for chronic conditions, which proves to be a steady seller for the market and continues to generate revenue returns. The use of cardiovascular drugs has also increased the prevalence of hypertension. There is a high demand for blood thinners in the market due to the increasing incidence of cardiovascular diseases. The increasing life expectancy of the elderly population has increased the demand for cardiovascular drugs. The increasing prevalence of cardiovascular disease in children has boosted the sales of these emergency drugs. Hypertensive drugs are difficult to discontinue, which helps maintain supply and demand.

On the basis of region, global cardiovascular drugs market is divided into North America, Europe, Asia Pacific, Latin America, and MEA. North America has witnessed the highest growth in the global cardiovascular drugs market due to the high prevalence of cardiovascular disorders in the population. Due to increasing industrialization and the popularity of fast food, the prevalence of high blood pressure and other heart diseases has increased. People's sedentary lifestyle choices, along with poor eating habits, have increased the risk of cardiovascular disease, increasing the demand for these treatments.